Market Overview - Southbound funds traded approximately HKD 138.285 billion today, a significant increase of about HKD 21.8 billion compared to the previous day, accounting for 39.75% of the total turnover of the Hang Seng Index, which has been below 40% for several consecutive days [2] - Despite the Hong Kong stock market accelerating downward, southbound funds saw a net inflow of approximately HKD 1.907 billion, with the Shanghai-Hong Kong Stock Connect recording a net inflow of about HKD 2.738 billion, while the Shenzhen-Hong Kong Stock Connect experienced a net outflow of approximately HKD 0.83 billion [2] Individual Stock Performance - Tencent Holdings (0700.HK) saw a significant net buy of HKD 1.304 billion, while its stock price fell by 1.24% [2][3] - Xiaomi Group-W (01810.HK) had a net buy of HKD 0.278 billion, with a stock price decline of 1.24% [2][3] - Huahong Semiconductor (01347.HK) experienced a net outflow of HKD 0.615 billion and a sharp decline of 11.24% [2][4] - Zijin Mining (02899.HK) had a net outflow of HKD 0.464 billion, with a stock price drop of 5.58% [2][4] - CSPC Pharmaceutical Group (01093.HK) saw a net outflow of HKD 0.393 billion and a decline of 4.69% [2][4] - Alibaba-W (09988.HK) experienced a net outflow of HKD 0.329 billion, with a stock price decrease of 3.49% [2][4] - SMIC (00981.HK) had a net outflow of HKD 0.162 billion, with a decline of 4.24% [2][4] Trading Activity - In the top ten active stocks on the Hong Kong Stock Connect (Shanghai), Alibaba-W had a net outflow of HKD 0.816 billion, while Tencent Holdings had a net inflow of HKD 0.880 billion [5] - On the Shenzhen Stock Connect, Alibaba-W recorded a net inflow of HKD 0.488 billion, while Huahong Semiconductor had a significant net outflow of HKD 0.554 billion [5]

Summary of Key Points Core Viewpoint - The Hong Kong stock market experienced significant net inflows from northbound capital, with a total net buy of HKD 19.07 billion on February 2, 2023, indicating strong investor interest in certain stocks while others faced net sell-offs [1]. Group 1: Northbound Capital Activity - Northbound capital recorded a net buy of HKD 27.38 billion through the Shanghai Stock Connect and a net sell of HKD 8.3 billion through the Shenzhen Stock Connect [1]. - The most bought stocks included Tencent (00700), Xiaomi Group-W (01810), and China Life (02628) [1]. - The most sold stocks were Hua Hong Semiconductor (01347), Zijin Mining (02899), and CSPC Pharmaceutical Group (01093) [1]. Group 2: Individual Stock Performance - Alibaba-W (09988) had a net sell of HKD 3.28 billion, with plans to invest HKD 30 billion in a "Spring Festival Treat Plan" [6][7]. - Tencent (00700) saw a net buy of HKD 13.03 billion, boosted by the launch of its "Yuanbao" Spring Festival red envelope activity, which is expected to increase downloads and user engagement [4]. - China Life (02628) received a net buy of HKD 1.87 billion, supported by positive forecasts for its individual insurance sales [5]. - Hua Hong Semiconductor (01347) faced a net sell of HKD 6.15 billion, amid tightening order reviews from major chip manufacturers [6]. - Zijin Mining (02899) experienced a net sell of HKD 4.64 billion, as it announced plans to issue USD 1.5 billion zero-coupon convertible bonds for project financing [7].

Group 1 - The core viewpoint of the report is that Bank of America Securities has raised the target price for CSPC Pharmaceutical Group (01093) from HKD 8.5 to HKD 9.1, while maintaining a "Underperform" rating due to sales pressure on the existing product portfolio and limited short-term contributions from the R&D pipeline [1] - The report highlights a collaboration agreement between CSPC and AstraZeneca to develop innovative long-acting peptide drugs, with a total agreement value of up to USD 18.5 billion [1] - Under the agreement, CSPC will receive an upfront payment of USD 1.2 billion and is eligible for up to USD 3.5 billion in potential R&D milestone payments, as well as up to USD 13.8 billion in potential sales milestone payments [1] Group 2 - The report indicates that CSPC announced three potential out-licensing transactions last May, and this agreement is the second transaction to be realized, although the realization has been delayed compared to expectations [1] - Due to the assets in the agreement being in the early stages, the report does not include related revenue in its forecasts, only accounting for the upfront payment, while raising the revenue and net profit forecasts for 2026 by 27.9% and 107.2%, respectively [1]

Group 1 - The core viewpoint of the article is that the collaboration agreement between CSPC Pharmaceutical Group and AstraZeneca is valued at up to $18.5 billion, with CSPC receiving an upfront payment of $1.2 billion [1] - CSPC is eligible for up to $3.5 billion in potential research milestone payments and up to $13.8 billion in potential sales milestone payments [1] - This agreement is the second of three potential licensing deals announced by CSPC last May, although the realization of this agreement has been delayed compared to expectations [1] Group 2 - The assets involved in the agreement are in the early stages of development, leading the bank to exclude related revenue from forecasts, only incorporating the upfront payment [1] - As a result, the bank has raised its revenue and net profit forecasts for 2026 by 27.9% and 107.2%, respectively [1] - The target price for CSPC has been increased from HKD 8.5 to HKD 9.1, but the bank maintains a "underperform" rating due to existing product portfolio sales pressure and limited short-term contributions from the research pipeline [1]

Core Viewpoint - The report from China Merchants Securities International highlights a historic deal between CSPC Pharmaceutical Group (01093) and AstraZeneca (AZN.US), expressing optimism about the transaction but indicating the need for further details on the long-acting GLP-1 global development from either CSPC or AstraZeneca [1] Group 1: Transaction Details - CSPC's key clinical candidate in collaboration with AstraZeneca is SYH2082, a long-acting GLP-1R/GIPR dual agonist, which has entered Phase I clinical trials [1] - The report notes that there is limited understanding of the long-acting GLP-1 platform, as SYH2082 has just initiated Phase I research in China [1] Group 2: Investment Outlook - The firm maintains a "neutral" rating, citing short-term fundamental concerns despite a long-term positive outlook on "Chinese innovative drugs entering the global pipeline" [1] - Investors are advised to carefully examine the asset valuation factors that may have already been priced in by the market prior to the business development announcement [1] Group 3: Market Competition - The entry of siRNA into the obesity maintenance market poses a significant threat to all peptide-based solutions [1] - The report emphasizes that siRNA drugs targeting weight loss and muscle preservation may ultimately pressure peptide-based obesity therapies, with a focus on the progress of Arrowhead and Wave siRNA assets [1] - Investors are encouraged to monitor the future impact of siINHBE and siALK7 targets on the weight maintenance market [1]

Core Viewpoint - The report from China Merchants Securities International highlights a historic deal between CSPC Pharmaceutical Group (01093) and AstraZeneca (AZN.US), expressing optimism about the transaction but indicating the need for further details on the long-acting GLP-1 global development from either CSPC or AstraZeneca [1] Group 1: Transaction Details - CSPC's key clinical candidate in collaboration with AstraZeneca is SYH2082, a long-acting GLP-1R/GIPR dual agonist, which has entered Phase I clinical trials [1] - The report notes that there is limited understanding of the long-acting GLP-1 platform, as SYH2082 has just initiated Phase I research in China [1] Group 2: Investment Outlook - The firm maintains a "neutral" rating, citing short-term fundamental concerns despite a long-term positive outlook on "Chinese innovative drugs entering the global pipeline" [1] - Investors are advised to carefully examine the asset valuation factors that may have already been priced in by the market prior to the business development announcement [1] Group 3: Market Competition - The entry of siRNA into the obesity maintenance market poses a significant threat to all peptide-based solutions [1] - The report emphasizes that siRNA drugs targeting weight loss and muscle preservation may ultimately pressure peptide-based obesity therapies, with a focus on the progress of Arrowhead and Wave siRNA assets [1] - Investors are encouraged to monitor the future impact of siINHBE and siALK7 targets on the weight maintenance market [1]

Summary of CSPC Pharma (1093.HK) Conference Call Company Overview - **Company**: CSPC Pharma - **Ticker**: 1093.HK - **Industry**: Pharmaceuticals Key Points from the Conference Call Landmark Deal with AstraZeneca - CSPC signed a significant licensing agreement with AstraZeneca (AZN) for the development of long-acting peptide medicine using sustained-release delivery technology and AI-driven peptide drug discovery platform - CSPC will license out the ex-China rights of eight assets, including: - A once-monthly injectable weight management portfolio consisting of SYH2082 (GLP-1/GIP, progressing into phase 1) - Three pre-clinical assets with different mechanisms - Four additional new programs - CSPC will receive an upfront payment of **US$1.2 billion** and potential R&D/sales milestone payments of up to **US$17.3 billion**, plus double-digit royalties on net sales - This marks CSPC's third collaboration with AZN, following previous licensing deals for an Lp(a) inhibitor and AI technology collaboration [1][2] Stock Price Reaction - Following the deal announcement, CSPC's share price closed down by **-10.2%** on January 30, 2026 - Investor sentiment towards the deal was generally positive, citing: - AstraZeneca's focus on cardio-metabolism and sourcing differentiated assets from China - Record-breaking deal size for China-to-West therapeutic agreements - The decline in share price was attributed to high expectations built into the stock price prior to the announcement, with CSPC's share price having increased by **+43%** since December 16, 2025 [2] Long-Acting GLP-1 Class Differentiation - The competition in the GLP-1 class is intensifying, and potential differentiation for latecomers may arise from: - More convenient long-acting dosage forms - Indication differentiation with additional clinical benefits beyond weight loss - Commercial synergy from a comprehensive product portfolio - Leading players in the long-acting GLP-1 agonist space include maridebart cafraglutide (Amgen, in phase 3) and MET-097 (Pfizer, in phase 3) [3][7] Earnings Estimates and Valuation Changes - Earnings estimates for 2026E and 2027E have been revised upwards by **+85.5%** and **+5.3%**, respectively, to account for the upfront payment and potential higher collaboration income - The 12-month price target has been raised to **HK$11.87** from **HK$10.57**, based on a sum-of-the-parts (SOTP) valuation: - DCF-based valuation of **HK$6.7 billion** for NBP - **HK$77.7 billion** for new product wave with global value added for oral GLP-1 - **HK$36.3 billion** for legacy portfolio and generics business - API business valued at **HK$3.9 billion** based on a 4.7x 2026E P/E - The discount rate used for valuation is **9%** [8][9] Risks and Considerations - Key downside risks include: - Earlier-than-expected value-based pricing (VBP) for NBP - Slower-than-expected ramp-up of new products - Failure of major R&D projects - Greater-than-expected price cuts impacting generic drug sales - CSPC maintains a "Buy" rating despite these risks [9][10] Market Context - CSPC's market capitalization is approximately **HK$110.6 billion** (US$14.2 billion) - The company is positioned within the China Pharma & Biotech sector, with a notable M&A rank of **3** [10]

每经AI快讯，石药集团(01093.HK)早盘涨超5%，截至发稿，涨2.19%，报9.81港元，成交4.46亿港元。 ...

Core Viewpoint - Recently, Stone Pharmaceutical Group (01093) has seen a significant stock price increase due to a strategic partnership with AstraZeneca for the development and commercialization of eight innovative long-acting peptide drug projects outside of mainland China and Hong Kong/Macau [1] Group 1: Financial Details - AstraZeneca will pay a total of $1.2 billion in upfront payments and up to $3.5 billion in cumulative milestone payments for development and sales [1] - The subsidiary of Giant Bio (New Nuo Wei, 300765) is entitled to receive 35% of the upfront payment and subsequent milestone payments based on actual conditions [1] Group 2: Future Prospects - CICC anticipates that by 2025, the company will have achieved external licensing for oral small molecule GLP-1 ($120 million upfront), AstraZeneca strategic cooperation ($110 million upfront), irinotecan liposome ($15 million upfront), and ROR1ADC ($15 million upfront) [1] - The company's R&D pipeline includes advanced innovative assets such as EGFR ADC/SiRNA series, which are expected to continue generating external licensing opportunities and milestone revenue recognition [1]

Core Viewpoint - The recent partnership between Stone Pharmaceutical Group and AstraZeneca for the development and commercialization of eight innovative long-acting peptide drug projects is expected to significantly enhance the company's revenue potential through substantial upfront and milestone payments [1] Group 1: Financial Impact - Stone Pharmaceutical Group's stock rose over 5% in early trading, reflecting positive market sentiment regarding the AstraZeneca collaboration [1] - AstraZeneca will pay a total of $1.2 billion in upfront payments and up to $3.5 billion in cumulative milestone payments for the projects [1] - The company is projected to receive 35% of the initial payment from the collaboration, along with potential future milestone payments and royalties [1] Group 2: Development Pipeline - The company has successfully licensed out several projects, including oral small molecule GLP-1 and others, which are expected to generate significant revenue [1] - The research pipeline includes advanced innovative assets such as EGFR ADC and SiRNA series, indicating ongoing potential for further licensing agreements and milestone revenue recognition [1]